Search the Newsreel

Nomad Foods (NYSE:NOMD) Releases FY 2026 Earnings Guidance

Nomad Foods Reports Second Quarter 2026 Financial Results

Pricing and productivity drove a positive Adjusted Gross Margin inflection Cash generation remains strong with Adjusted Free Cash Flow conversion higher year-on-year WOKING, England, Aug. 13, 2026 /PRNewswire/ -- Nomad Foods Limited (NYSE: NOMD), today reported financial results for the three and six month …

Manomay Tex India Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Manomay Tex India Ltd June-Quarter Profit From Continuing Operations 49.5 Million Rupees

Nomura Holdings (NMR) hits ¥60B buyback cap and details treasury shares

Nomura Holdings has reached the ¥60 billion monetary cap for its current share repurchase program, having bought back 46,861,200 shares, representing 46.9% of the authorized share amount. The company did not repurchase any shares in July 2026, but disposed of 2,300 treasury shares due …

Telsey raises Williams-Sonoma stock price target on brand strength

Telsey has increased its price target for Williams-Sonoma (NYSE:WSM) to $255 from $225, maintaining an Outperform rating, citing the company's strong brand engagement and healthy affluent consumer base. The firm expects favorable Q2 fiscal 2026 trends, with contributions from resurgent brands like West Elm …

Western Wealth Management LLC Buys Shares of 5,642 Williams-Sonoma, Inc. $WSM

5 Revealing Analyst Questions From 10x Genomics’s Q2 Earnings Call

Nomura Holdings 1Q Pretax Pft Y211.54B Vs Pft Y160.28B

Nomura Holdings reported a first-quarter pretax profit of Y211.54 billion, an increase compared to the Y160.28 billion reported in the previous period. The article also mentions Unity Software's fourth-quarter earnings, with revenue increasing 35% year-over-year to $609 million, exceeding estimates, despite reporting a quarterly …

Bank of America Corp DE Reduces Stock Position in Fomento Economico Mexicano S.A.B. de C.V. $FMX

Nomad Foods: Q2 Earnings Snapshot

Nomad Foods Ltd. reported a net income of $56.4 million in its second quarter, translating to a profit of 41 cents per share. After adjusting for non-recurring costs, earnings were 45 cents per share. The frozen foods company also announced revenues of $841.3 million …

Oryzon Genomics, cotización y precio de la acción hoy [ORY]

Immunome (NASDAQ:IMNM) Reaches New 12-Month High Following Analyst Upgrade

Immunome (NASDAQ:IMNM) shares hit a new 52-week high of $28.04 after Truist Financial raised its price target to $38 from $37, maintaining a "Buy" rating. Despite a larger-than-expected quarterly loss and significant insider selling, analyst sentiment remains largely positive, with a consensus price target …

Immunome: Varegacestat Cuts Progression Or Death Risk 84% As FDA Decision Targets April 2027

Immunome is advancing varegacestat for desmoid tumors after its Phase 3 RINGSIDE study showed an 84% reduction in disease progression or death risk. The FDA has accepted the New Drug Application with a target action date of April 28, 2027, and the company plans …

Fomento Economico Mexicano (NYSE:FMX) Director Purchases $248,073.00 in Stock

Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 10,125 Shares

Immunome (NASDAQ:IMNM) Director Isaac Barchas sold 15,248 shares of the company's stock on August 7th for over $397,000, reducing his direct holdings by 17.39%. This sale was part of a pre-arranged Rule 10b5-1 plan, and he has sold more than 320,000 shares since late …

Insider Selling: Immunome (NASDAQ:IMNM) Director Sells $1,633,892.93 in Stock

Immunome (NASDAQ:IMNM) Director Isaac Barchas sold 11,048 shares of the company's stock for over $301,000, reducing his holdings by 10.7%. This sale is part of a series of transactions under a pre-arranged trading plan, totaling about $2.6 million from August 10-12. Despite the sales …

Insider Selling: Immunome (NASDAQ:IMNM) Director Sells 11,048 Shares

Immunome (NASDAQ:IMNM) Director Isaac Barchas sold 11,048 shares of the company's stock for over $301,000, reducing his holdings by 10.7%. This sale is part of a series of transactions under a pre-arranged trading plan, totaling about $2.6 million from August 10-12. Despite the sales …

Immunome director Isaac Barchas sells over $2.1m in shares By Investing.com

Immunome director Isaac Barchas sold over $2.19 million worth of company shares in August 2026 through pre-arranged Rule 10b5-1 trading plans. These sales included shares held indirectly by AMBHMC II LLC and directly by Barchas, following which he directly holds 92,211 shares. The sales …

Williams-Sonoma (WSM) Stock Falls Amid Market Uptick: What Investors Need to Know

Williams-Sonoma (WSM) shares fell by 2.17% on the most recent trading day, underperforming the S&P 500's gain, despite the stock's 13.73% increase over the past month. Investors are anticipating upcoming earnings, with analysts projecting a 2.5% year-over-year earnings growth and a 4.14% revenue increase. …

Williams-Sonoma Inc (WSM) rallies 10.1% in weekly context

The specialty retailer’s latest close keeps the 52-week setup firm, with medium-term performance still stronger than the latest turnover picture.

NeoGenomics Senior VP & Chief Accounting Officer Gregory Aunan Sells 80% Of Holding

NeoGenomics' Senior VP & Chief Accounting Officer, Gregory Aunan, recently sold US$321k worth of shares, representing an 80% reduction in his holdings at an average price of US$16.07. This significant insider selling event, occurring slightly below the current share price of US$16.53, raises caution …

Immunome, Inc. Stock 12‑Month Price Target Raised to $36.31, Implies 38% Upside

Immunome, Inc.'s average 12-month price target has been increased to $36.31 by 13 analysts, up from $35.77, with individual forecasts ranging from $30 to $40 per share. This new target suggests a potential upside of approximately 38% from its August 11 closing price. The …

Immunome (NASDAQ:IMNM) Stock Price Expected to Rise, Truist Financial Analyst Says

Maxim Group Maintains Bionano Genomics(BNGO.US) With Buy Rating, Maintains Target Price $4

Maxim Group has reiterated its Buy rating for Bionano Genomics (BNGO.US), along with a maintained target price of $4. This indicates a continued positive outlook from the firm regarding the company's stock performance and valuation.

Immunome stock hits 52-week high at 27.68 USD

Immunome Inc. (IMNM) stock has reached a new 52-week high of $27.68, reflecting significant investor confidence with a 1-year change of 175.42%. Despite InvestingPro analysis suggesting the shares may be overvalued, analysts have revised earnings upwards, with price targets ranging from $30 to $40. …

Former Williams-Sonoma Executive Admits $16M Fraud Scheme

A former Williams-Sonoma executive, Eric Marsiglia, has pleaded guilty to wire fraud and money laundering conspiracies totaling over $16 million in losses. Marsiglia admitted to receiving $12.2 million in kickbacks for steering company business and diverting $4.1 million in real estate commissions. He faces …

Immunome Inc. SEC Filing (Aug 12, 2026)

This article reports on an Immunome Inc. SEC Filing (Form 144) submitted on August 12, 2026, which details a proposed sale of 11,048 shares of common stock with an aggregate market value of $301,058.00. The filing, accepted by the SEC EDGAR at 11:40 AM …

Immunome (NASDAQ:IMNM) Shares Gap Down on Disappointing Earnings

HONG KONG ECONOMIC TIME HLDG To Go Ex-Dividend On August 13th, 2026 With 0.00513 USD Dividend Per Share

Freenome targets lung screening gap; only about 18% of U.S. adults recommended get screened

Freenome has received FDA Breakthrough Device Designation for its investigational SimpleScreen™ Lung test, a blood-based screening tool for lung cancer. The test is designed for high-risk adults aged 50-80 with a significant smoking history who are not currently undergoing recommended screening, aiming to address …

Immunome Inc. Q2 2026: Revenue $0 Net loss $73.1M, EPS $(0.65) — 10-Q Summary

Immunome Inc. reported Q2 2026 financial results, showing zero revenue and a net loss of $73.1 million, or $(0.65) per diluted share. This is a decline compared to the prior year's Q2 2025, which had $4 million in revenue and a net loss of …

Nomad Foods earnings in spotlight as Europe frozen food leader pivots

Nomad Foods is scheduled to release its second-quarter results, with investors keenly observing whether the frozen food company can meet its recently increased guidance and demonstrate progress in its operational turnaround. Analysts anticipate earnings of €0.33 per share on revenue of €710.9 million, indicating …

These Analysts Think Metagenomi Therapeutics, Inc.'s (NASDAQ:MGX) Sales Are Under Threat

Analysts have significantly cut their revenue and increased their loss per share estimates for Metagenomi Therapeutics, Inc. (NASDAQ:MGX) for 2026. The new consensus predicts a substantial 43% decline in revenue and increased losses per share compared to previous forecasts. This revision suggests a more …

US$49.54 - That's What Analysts Think 10x Genomics, Inc. (NASDAQ:TXG) Is Worth After These Results

Williams-Sonoma (WSM) Receives a Hold from Wells Fargo